Cachexia News and Research

RSS

Cachexia is a condition which denotes the excessive loss of weight. It occurs because of the depletion of adipose tissue and muscle mass in people who are not trying to lose weight.

Ohr Pharmaceutical to present interim data from ongoing Phase II clinical trial of OHR/AVR118

Ohr Pharmaceutical Inc., announced that interim data from the company's ongoing Phase II clinical trial of OHR/AVR118 for the treatment of Cachexia, will be presented at the 5th annual meeting of the Society on Cachexia and Wasting Disorders (SCWD), which will be held in Barcelona December 5 - December 8, 2009.

2 Dec 2009

OSEO awards fund for Galapagos NV's antibody therapeutics program

Galapagos NV announces that its antibody therapeutics program with MorphoSys and SARM program have been awarded funding by the French governmental organization OSEO.

26 Nov 2009

Ohr Pharmaceutical to develop OHR/AVR118 for cachexia treatment

Ohr Pharmaceutical Inc. is developing OHR/AVR118 for treatment of cachexia based on technology acquired earlier this year from Advanced Viral Research Corp. OHR/AVR118 has shown excellent therapeutic efficacy and safety in human clinical trials in over 100 patients with applications for cachexia in Cancer and AIDS patients, as well as Rheumatoid Arthritis.

24 Nov 2009

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

Ligand Pharmaceuticals Incorporated today announced that data from a preclinical study on its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation at the 62nd Annual Meeting of the Gerontology Society of America in Atlanta. LGD-4033 exhibited desirable in vivo efficacy on skeletal muscle and bone measurements in animal models of male hypogonadism and postmenopausal osteoporosis.

20 Nov 2009

Treatment of iron deficiency can improve symptoms and quality of life in CHF patients

Intravenous (I.V.) iron treatment with ferric carboxymaltose to reverse iron deficiency can significantly improve symptoms, exercise tolerance and quality of life for chronic heart failure (CHF) patients, researchers said in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.

19 Nov 2009

Findings suggest athletes abuse non-approved therapeutic compounds for performance enhancing effects

Researchers from the German Sport University Cologne in Germany found that non-steroidal and tissue-selective anabolic agents such as Selective Androgen Receptor Modulators (SARMs) are being sold on the black market for their performance enhancing qualities.

19 Nov 2009

Rosiglitazone slows progression of cachexia in cancer affected mice

Insulin resistance, the hallmark of type 2 diabetes and a condition often associated with obesity, is paradoxically also an apparent contributor to muscle wasting and severe fat loss that accompanies some cancers, according to new research.

27 Sep 2009

Charley's Fund and the Nash Avery Foundation to support investigation of Galapagos' SARM candidate drug

Galapagos NV (Euronext: GLPG), Charley's Fund Inc. and the Nash Avery Foundation announced today that they will collaborate to investigate the potential effectiveness of Galapagos' SARM candidate drug, G100192, in treating Duchenne muscular dystrophy. G100192 is an orally-available small molecule therapeutic, which has demonstrated successful Proof of Concept in pre-clinical studies for cachexia (the loss of weight and muscle mass).

17 Sep 2009

Phase 1 single dose clinical trial of Acceleron Pharma's ACE-031 increases lean body mass

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced preliminary results from the ACE-031 Phase 1 single dose clinical trial indicating that ACE-031 was safe and well-tolerated at all dose levels and increased lean body mass.

2 Sep 2009

New data on link between cancer and nutrition

European experts in cancer and nutrition are meeting in Zurich, Switzerland late this month to discuss cutting-edge research in one of the most important and fiercely debated topics in cancer prevention: the link between diet and cancer.

12 Mar 2009

Pathologically elevated blood fat levels in obesity: Researchers discover molecular causes

Scientists at the German Cancer Research Center have discovered a mechanism in liver metabolism that is responsible for pathologically elevated blood fat levels found in severe metabolic disorders.

9 Feb 2009

Too much weight loss can be a bad thing

Doctors are not doing enough to pick up on problems with excessive weight loss, says a Saint Louis University physician who helped draft recent guidelines to diagnose the condition called "cachexia" (kuh-kex-ee-uh).

21 Jan 2009

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

Incyte Corporation will present updated results from an ongoing Phase II trial of INCB18424, its selective, orally available Janus kinase (JAK) inhibitor, in patients with myelofibrosis (MF) at the 50th American Society of Hematology (ASH) Annual Meeting.

8 Dec 2008

New blood test identifies sickest heart failure patients in ER

A new blood test identifies the sickest heart failure patients better than tests now used in emergency departments, researchers reported at the American Heart Association's Scientific Sessions 2008. Results of the Mid-Regional pro-Adrenomedullin (proADM) versus BNP and NTproBNP as Prognosticator in Heart Failure Patients: Results of the BACH Multinational Trial were presented as a late-breaking clinical trial.

11 Nov 2008

New diagnostic tools and biomarkers

Patients presenting shortness of breath on arrival at the emergency department (ED) can gain from improved diagnosis allowing physicians to distinguish congestive heart failure patients from those presenting pneumonia.

1 Sep 2008

Researchers discover molecular basis of limb-girdle muscular dystrophy

A team of French and German researchers report in the May 2008 print issue of The FASEB Journal that people with limb-girdle muscular dystrophy are missing a protein called c-FLIP, which the body uses to prevent the loss of muscle tissue.

30 Apr 2008

Nausea from chemotherapy explained

A new study from the Monell Center increases understanding of the biological mechanisms responsible for the nausea and vomiting that often afflict patients undergoing chemotherapy.

4 Feb 2008

Fish oil may help people with chronic kidney disease

Fish oil, it's been touted as an answer to Alzheimers, arthritis and even weight-loss but now a Queensland University of Technology researcher will test its health benefits in people with chronic kidney disease.

1 May 2007

Targeted therapies improve colon cancer survival rates

People diagnosed with advanced colorectal cancer that has spread to distant organs, such as White House spokesman Tony Snow, are much more likely to survive today than even just a few years ago, due to the recent and continued emergence of improved therapies, say cancer experts.

3 Apr 2007

Why anti-obesity cortisol reducing supplements do not work

Researchers at Oregon Health & Science University have revealed that the cortisol/obesity connection, touted by many weight-loss supplement marketers, may be even more tenuous than first thought.

2 Feb 2006